{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:45:46Z","timestamp":1790142346029,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:00:00Z","timestamp":1407196800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-565","type":"journal-article","created":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T13:01:43Z","timestamp":1407243703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Constitutive AKT activation in follicular lymphoma"],"prefix":"10.1186","volume":"14","author":[{"given":"Ouardia I","family":"Yahiaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques A","family":"Nun\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Castanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Broussais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie J","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Naimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9da","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Xerri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,5]]},"reference":[{"issue":"14","key":"4748_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2010.33.3252","volume":"29","author":"H Nogai","year":"2011","unstructured":"Nogai H, D\u00f6rken B, Lenz G: Pathogenesis of Non-Hodgkin\u2019s Lymphoma. J Clin Oncol. 2011, 29 (14): 1803-1811.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4748_CR2","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/leu.2010.154","volume":"24","author":"PM Bhende","year":"2010","unstructured":"Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B: The Dual PI3k\/mTOR inhibitor, NVP-BEZ235 is Efficacious against Non Hodgkin Lymphoma. Leukemia. 2010, 24 (10): 1781-1784.","journal-title":"Leukemia"},{"key":"4748_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1756-8722-6-55","volume":"6","author":"M Desai","year":"2013","unstructured":"Desai M, Newberry KJ, Romaguera J, Zhang L, Ou Z, Wang M: Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. J Hematol Oncol. 2013, 6: 55-","journal-title":"J Hematol Oncol"},{"issue":"7","key":"4748_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL: The Phosphatidylinositol 3 Kinase AKT Pathway in human cancer. Nat Rev Cancer. 2002, 2 (7): 489-501.","journal-title":"Nat Rev Cancer"},{"key":"4748_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0065-230X(09)02002-8","volume":"102","author":"BH Jiang","year":"2009","unstructured":"Jiang BH, Liu LZ: PI3K\/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res. 2009, 102: 19-65.","journal-title":"Adv Cancer Res"},{"issue":"1","key":"4748_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1006\/excr.1999.4701","volume":"253","author":"B Vanhaesebroeck","year":"1999","unstructured":"Vanhaesebroeck B, Waterfield MD: Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999, 253 (1): 239-254.","journal-title":"Exp Cell Res"},{"issue":"8","key":"4748_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC: The evolution of Phosphatidylinositol 3-Kinase as regulators of growth and metabolism. Nat Rev Genet. 2006, 7 (8): 606-619.","journal-title":"Nat Rev Genet"},{"issue":"5573","key":"4748_CR8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley LC: The phosphoinositide 3-kinase pathway. Science. 2002, 296 (5573): 1655-1657.","journal-title":"Science"},{"issue":"6","key":"4748_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1023\/B:APPT.0000045801.15585.dd","volume":"9","author":"M Osaki","year":"2004","unstructured":"Osaki M, Oshimura M, Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis. 2004, 9 (6): 667-676.","journal-title":"Apoptosis"},{"issue":"5670","key":"4748_CR10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004, 304 (5670): 554-","journal-title":"Science"},{"issue":"21","key":"4748_CR11","doi-asserted-by":"publisher","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","volume":"64","author":"IG Campbell","year":"2004","unstructured":"Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004, 64 (21): 7678-7681.","journal-title":"Cancer Res"},{"issue":"3","key":"4748_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/ijc.10962","volume":"104","author":"DS Byun","year":"2003","unstructured":"Byun DS, Cho K, Ryu BK, Lee MG, Park JI, Chae KS, Kim HJ, Chi SG: Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer. 2003, 104 (3): 318-327.","journal-title":"Int J Cancer"},{"issue":"10","key":"4748_CR13","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1164\/rccm.200404-487OC","volume":"170","author":"PP Massion","year":"2004","unstructured":"Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, Shakthour B, Edgerton ME, Ninan M, Andersen JJ, Gonzalez AL: Early involvement of the phosphatidylinositol 3-kinase\/Akt pathway in lung cancer progression. Am J Respir Crit Care Med. 2004, 170 (10): 1088-1094.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"4748_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ijc.20711","volume":"114","author":"JM Pedrero","year":"2005","unstructured":"Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, Gonzalez MV: Frequent genetic and biochemical alterations of the PI3K\/AKT\/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer. 2005, 114 (2): 242-248.","journal-title":"Int J Cancer"},{"issue":"23","key":"4748_CR15","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/sj.onc.1203597","volume":"19","author":"YY Ma","year":"2000","unstructured":"Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY: PIK3CA as an oncogene in cervical cancer. Oncogene. 2000, 19 (23): 2739-2744.","journal-title":"Oncogene"},{"issue":"22","key":"4748_CR16","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1093\/jnci\/91.22.1922","volume":"91","author":"IU Ali","year":"1999","unstructured":"Ali IU, Schriml LM, Dean M: Mutational spectra of PTEN\/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst. 1999, 91 (22): 1922-1932.","journal-title":"J Natl Cancer Inst"},{"key":"4748_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","volume":"4","author":"N Chalhoub","year":"2009","unstructured":"Chalhoub N, Baker SJ: PTEN and the PI3-Kinase Pathway in Cancer. Annu Rev Pathol. 2009, 4: 127-150.","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"4748_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ijc.2910640412","volume":"64","author":"A Bellacosa","year":"1995","unstructured":"Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995, 64 (4): 280-285.","journal-title":"Int J Cancer"},{"issue":"5","key":"4748_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/sj.leu.2402874","volume":"17","author":"YH Min","year":"2003","unstructured":"Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK, Lee ST, Lee MH, Hahn JS, Ko YW: Constitutive phosphorylation of Akt\/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia. 2003, 17 (5): 995-997.","journal-title":"Leukemia"},{"issue":"7152","key":"4748_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nature05933","volume":"448","author":"JD Carpten","year":"2007","unstructured":"Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007, 448 (7152): 439-444.","journal-title":"Nature"},{"issue":"5","key":"4748_CR21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/sj.leu.2402484","volume":"16","author":"M J\u00fccker","year":"2002","unstructured":"J\u00fccker M, S\u00fcdel K, Horn S, Sickel M, Wegner W, Fiedler W, Feldman RA: Expression of a mutated form of the p85\u03b1 regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin\u2019s lymphoma-derived cell line (CO). Leukemia. 2002, 16 (5): 894-901.","journal-title":"Leukemia"},{"issue":"20","key":"4748_CR22","first-page":"7426","volume":"61","author":"AJ Philp","year":"2001","unstructured":"Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ, Phillips WA: The phosphatidylinositol 3\u2032-kinase p85\u03b1 gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001, 61 (20): 7426-7429.","journal-title":"Cancer Res"},{"issue":"10","key":"4748_CR23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","volume":"3","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Velculescu VE: Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004, 3 (10): 1221-1224.","journal-title":"Cell Cycle"},{"issue":"1","key":"4748_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/01.cco.0000198021.99347.b9","volume":"18","author":"Y Samuels","year":"2006","unstructured":"Samuels Y, Ericson K: Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006, 18 (1): 77-82.","journal-title":"Curr Opin Oncol"},{"issue":"11","key":"4748_CR25","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1038\/sj.leu.2404873","volume":"21","author":"J Abubaker","year":"2007","unstructured":"Abubaker J, Bavi PP, Al-Harbi S, Siraj AK, Al-Dayel F, Uddin S, Al-Kuraya K: PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia. 2007, 21 (11): 2368-2370.","journal-title":"Leukemia"},{"issue":"13","key":"4748_CR26","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1182\/blood-2006-04-016907","volume":"108","author":"S Uddin","year":"2006","unstructured":"Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, Ezzat A, Bavi P, Al-Kuraya KS: Role of phosphatidylinositol 3'-kinase\/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006, 108 (13): 4178-4186.","journal-title":"Blood"},{"issue":"5","key":"4748_CR27","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","volume":"108","author":"M Rudelius","year":"2006","unstructured":"Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES, Quintanilla-Martinez L, Raffeld M: Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood. 2006, 108 (5): 1668-1676.","journal-title":"Blood"},{"issue":"18","key":"4748_CR28","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","volume":"15","author":"A Psyrri","year":"2009","unstructured":"Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos CK, Argyriou P, Pectasides D, Harhalakis N, Pappa V, Kolialexi A, Economopoulou C, Kontsioti F, Maratou E, Dimitriadis G, Economopoulou P, Economopoulos T: Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. 2009, 15 (18): 5724-5732.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4748_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/labinvest.3700051","volume":"84","author":"H Zha","year":"2004","unstructured":"Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E, Liotta LA, Jaffe ES: Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest. 2004, 84 (2): 235-244.","journal-title":"Lab Invest"},{"issue":"16","key":"4748_CR30","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1158\/1078-0432.CCR-05-0637","volume":"11","author":"C Gulmann","year":"2005","unstructured":"Gulmann C, Espina V, Petricoin E, Longo DL, Santi M, Knutsen T, Raffeld M, Jaffe ES, Liotta LA, Feldman AL: Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res. 2005, 11 (16): 5847-5855.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4748_CR31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","volume":"117","author":"BJ Lannutti","year":"2011","unstructured":"Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA: CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011, 117 (2): 591-594.","journal-title":"Blood"},{"issue":"21","key":"4748_CR32","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood.V116.21.1777.1777","volume":"116","author":"B Kahl","year":"2010","unstructured":"Kahl B, Byrd JC, Flinn IW, Wagner-Johnston N, Spurgeon S, Benson DM, Furman RR, Brown JR, Coutre S, Lannutti B, Giese NA, Ulrich RG, Webb HK, Peterman S, Holes L, Yu AS: Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of Phosphatidylinositol 3-Kinase P110 \u03b4, in patients with relapsed or refractory Non-Hodgkin lymphoma [abstract]. Blood. 2010, 116 (21): 1777-ASH Annual Meeting Abstracts","journal-title":"Blood"},{"issue":"1","key":"4748_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/13543784.2012.640318","volume":"21","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Furman M, Winer ES: CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012, 21 (1): 15-22.","journal-title":"Expert Opin Investig Drugs"},{"key":"4748_CR34","first-page":"523","volume-title":"Hematology Am Soc Hematol Educ Program","author":"ES Jaffe","year":"2009","unstructured":"Jaffe ES: The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009, 523-531."},{"issue":"12","key":"4748_CR35","doi-asserted-by":"publisher","first-page":"7681","DOI":"10.4049\/jimmunol.0802203","volume":"182","author":"A G\u00e9rard","year":"2009","unstructured":"G\u00e9rard A, Ghiotto M, Fos C, Guittard G, Compagno D, Galy A, Lemay S, Olive D, Nun\u00e8s JA: Dok-4 is a novel negative regulator of T cell activation. J Immunol. 2009, 182 (12): 7681-7689.","journal-title":"J Immunol"},{"issue":"12","key":"4748_CR36","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/nrc1753","volume":"5","author":"AG Bader","year":"2005","unstructured":"Bader AG, Kang S, Zhao L, Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005, 5 (12): 921-929.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"4748_CR37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1750-3639.2003.tb00481.x","volume":"13","author":"CB Knobbe","year":"2003","unstructured":"Knobbe CB, Reifenberger G: Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase\/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 2003, 13 (4): 507-518.","journal-title":"Brain Pathol"},{"key":"4748_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0065-230X(05)94002-5","volume":"94","author":"A Bellacosa","year":"2005","unstructured":"Bellacosa A, Kumar CC, Di Cristofano A, Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005, 94: 29-86.","journal-title":"Adv Cancer Res"},{"issue":"2","key":"4748_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/sj.leu.2404054","volume":"20","author":"P Cornillet-Lefebvre","year":"2006","unstructured":"Cornillet-Lefebvre P, Cuccuini W, Bardet V, Tamburini J, Gillot L, Ifrah N, Nguyen P, Dreyfus F, Mayeux P, Lacombe C, Bouscary D: Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations. Leukemia. 2006, 20 (2): 374-376.","journal-title":"Leukemia"},{"issue":"31","key":"4748_CR40","doi-asserted-by":"publisher","first-page":"19236","DOI":"10.1074\/jbc.272.31.19236","volume":"272","author":"D Chantry","year":"1997","unstructured":"Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW, Cooper JA, Hoekstra MF: p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem. 1997, 272 (31): 19236-19241.","journal-title":"J Biol Chem"},{"issue":"6","key":"4748_CR41","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1084\/jem.20020805","volume":"196","author":"E Clayton","year":"2002","unstructured":"Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, Humphries LA, Rawlings D, Reynolds H, Vigorito E, Turner M: A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med. 2002, 196 (6): 753-763.","journal-title":"J Exp Med"},{"key":"4748_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1126\/scisignal.286pl3","volume":"2","author":"G Firaguay","year":"2009","unstructured":"Firaguay G, Nunes JA: Analysis of signaling events by dynamic phosphoflow cytometry. Sci Signal. 2009, 2: 3-","journal-title":"Sci Signal"},{"issue":"1","key":"4748_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molcel.2005.03.008","volume":"18","author":"T Gao","year":"2005","unstructured":"Gao T, Furnari F, Newton AC: PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005, 18 (1): 13-24.","journal-title":"Mol Cell"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-565.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-565\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T22:46:30Z","timestamp":1598136390000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,5]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["4748"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-565","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,5]]},"article-number":"565"}}